James Bhatt

James Bhatt contributed to the translational development of olaparib as a maintenance therapy for BRCA-mutated ovarian cancer through the SOLO1 and SOLO2 trials. His research bridged preclinical PARP inhibitor biology with clinical biomarker strategies including companion diagnostic development for BRCA testing. He has also studied the mechanisms by which PARP inhibitors are synergistic with platinum-based chemotherapy in homologous recombination-deficient ovarian cancer. His industry contributions accelerated FDA approval of the first maintenance PARP inhibitor for ovarian cancer.